1. Home
  2. RCEL vs HCAT Comparison

RCEL vs HCAT Comparison

Compare RCEL & HCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCEL
  • HCAT
  • Stock Information
  • Founded
  • RCEL N/A
  • HCAT 2008
  • Country
  • RCEL United States
  • HCAT United States
  • Employees
  • RCEL N/A
  • HCAT N/A
  • Industry
  • RCEL Medical/Dental Instruments
  • HCAT Computer Software: Programming Data Processing
  • Sector
  • RCEL Health Care
  • HCAT Technology
  • Exchange
  • RCEL Nasdaq
  • HCAT Nasdaq
  • Market Cap
  • RCEL 308.6M
  • HCAT 318.2M
  • IPO Year
  • RCEL N/A
  • HCAT 2019
  • Fundamental
  • Price
  • RCEL $9.75
  • HCAT $5.23
  • Analyst Decision
  • RCEL Buy
  • HCAT Buy
  • Analyst Count
  • RCEL 5
  • HCAT 10
  • Target Price
  • RCEL $17.25
  • HCAT $10.20
  • AVG Volume (30 Days)
  • RCEL 191.4K
  • HCAT 685.5K
  • Earning Date
  • RCEL 02-13-2025
  • HCAT 02-26-2025
  • Dividend Yield
  • RCEL N/A
  • HCAT N/A
  • EPS Growth
  • RCEL N/A
  • HCAT N/A
  • EPS
  • RCEL N/A
  • HCAT N/A
  • Revenue
  • RCEL $64,251,000.00
  • HCAT $302,062,000.00
  • Revenue This Year
  • RCEL $62.11
  • HCAT $5.66
  • Revenue Next Year
  • RCEL $31.19
  • HCAT $9.90
  • P/E Ratio
  • RCEL N/A
  • HCAT N/A
  • Revenue Growth
  • RCEL 28.14
  • HCAT 4.15
  • 52 Week Low
  • RCEL $7.51
  • HCAT $5.20
  • 52 Week High
  • RCEL $18.93
  • HCAT $9.24
  • Technical
  • Relative Strength Index (RSI)
  • RCEL 50.10
  • HCAT 36.55
  • Support Level
  • RCEL $8.37
  • HCAT $5.25
  • Resistance Level
  • RCEL $11.25
  • HCAT $5.68
  • Average True Range (ATR)
  • RCEL 0.55
  • HCAT 0.26
  • MACD
  • RCEL 0.22
  • HCAT 0.03
  • Stochastic Oscillator
  • RCEL 47.92
  • HCAT 4.96

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

About HCAT Health Catalyst Inc

Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.

Share on Social Networks: